Disease-free survival
7.79–not, death, tumor
TUMOR
Among Japanese patients, the median DFS was 29.67 months (95% CI 7.79–not reached [NR]) in the nivolumab group and 9.72 months (95% CI 4.73–NR) in the placebo group (Among patients with tumor PD-L1 expression level of 1% or more (nivolumab, DFS according to treatment in all randomized Japanese patients. CI, confidence interval; DFS, disease-free survival; NR, not reached.DFS according to treatment in Japanese patients with tumor programmed death ligand 1 expression of 1% or more. CI, confidence interval; DFS, disease-free survival; NR, not reached.NUTRFS according to treatment in all randomized Japanese patients. CI, confidence interval; NR, not reached; NUTRFS, non-urothelial tract recurrence-free survival.NUTRFS according to treatment in Japanese patients with tumor programmed death ligand 1 expression of 1% or more. CI, confidence interval; NR, not reached; NUTRFS, non-urothelial tract recurrence-free survival.